160 related articles for article (PubMed ID: 10405144)
21. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
[TBL] [Abstract][Full Text] [Related]
22. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
[TBL] [Abstract][Full Text] [Related]
23. Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
Mirallié E; Saï-Maurel C; Faivre-Chauvet A; Regenet N; Chang CH; Goldenberg DM; Chatal JF; Barbet J; Thedrez P
Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):901-9. PubMed ID: 15864584
[TBL] [Abstract][Full Text] [Related]
24. Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide.
Karacay H; McBride WJ; Griffiths GL; Sharkey RM; Barbet J; Hansen HJ; Goldenberg DM
Bioconjug Chem; 2000; 11(6):842-54. PubMed ID: 11087333
[TBL] [Abstract][Full Text] [Related]
25. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
[TBL] [Abstract][Full Text] [Related]
26. Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental and clinical results.
Le Doussal JM; Barbet J; Delaage M
Int J Cancer Suppl; 1992; 7():58-62. PubMed ID: 1428406
[TBL] [Abstract][Full Text] [Related]
27. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
[TBL] [Abstract][Full Text] [Related]
28. Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy.
Janevik-Ivanovska E; Gautherot E; Hillairet de Boisferon M; Cohen M; Milhaud G; Tartar A; Rostene W; Barbet J; Gruaz-Guyon A
Bioconjug Chem; 1997; 8(4):526-33. PubMed ID: 9258451
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
Kraeber-Bodéré F; Faivre-Chauvet A; Ferrer L; Vuillez JP; Brard PY; Rousseau C; Resche I; Devillers A; Laffont S; Bardiès M; Chang K; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3973S-81S. PubMed ID: 14506196
[TBL] [Abstract][Full Text] [Related]
30. Radioimmunotherapy of small-cell lung cancer xenografts using 131I-labelled anti-NCAM monoclonal antibody 123C3.
Kwa HB; Verhoeven AH; Storm J; van Zandwijk N; Mooi WJ; Hilkens J
Cancer Immunol Immunother; 1995 Sep; 41(3):169-74. PubMed ID: 7553686
[TBL] [Abstract][Full Text] [Related]
31. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
32. Targeting BCL1 lymphoma with anti-idiotype antibodies: biodistribution kinetics of directly labeled antibodies and bispecific antibody-targeted bivalent haptens.
Manetti C; Rouvier E; Gautherot E; Loucif E; Barbet J; Le Doussal JM
Int J Cancer; 1997 Jun; 71(6):1000-9. PubMed ID: 9185704
[TBL] [Abstract][Full Text] [Related]
33. Treatment of small-cell lung cancer xenografts with iodine-131-anti-neural cell adhesion molecule monoclonal antibody and evaluation of absorbed dose in tissue.
Hosono M; Endo K; Hosono MN; Kobayashi H; Shirato M; Sakahara H; Ueda R; Konishi J
J Nucl Med; 1994 Feb; 35(2):296-300. PubMed ID: 8295002
[TBL] [Abstract][Full Text] [Related]
34. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
Barbet J; Peltier P; Bardet S; Vuillez JP; Bachelot I; Denet S; Olivier P; Leccia F; Corcuff B; Huglo D; Proye C; Rouvier E; Meyer P; Chatal JF
J Nucl Med; 1998 Jul; 39(7):1172-8. PubMed ID: 9669389
[TBL] [Abstract][Full Text] [Related]
35. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
[TBL] [Abstract][Full Text] [Related]
36. Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44V6/anti-gallium chelate antibodies.
Klivényi G; Schuhmacher J; Patzelt E; Hauser H; Matys R; Moock M; Regiert T; Maier-Borst W
J Nucl Med; 1998 Oct; 39(10):1769-76. PubMed ID: 9776285
[TBL] [Abstract][Full Text] [Related]
37. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha.
Robert B; Mach JP; Mani JC; Ychou M; Folli S; Artus JC; Pèlegrin A
Cancer Res; 1996 Oct; 56(20):4758-65. PubMed ID: 8840995
[TBL] [Abstract][Full Text] [Related]
38. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate.
Boerman OC; Kranenborg MH; Oosterwijk E; Griffiths GL; McBride WJ; Oyen WJ; de Weijert M; Oosterwijk-Wakka J; Hansen HJ; Corstens FH
Cancer Res; 1999 Sep; 59(17):4400-5. PubMed ID: 10485489
[TBL] [Abstract][Full Text] [Related]
39. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
Blumenthal RD; Sharkey RM; Haywood L; Natale AM; Wong GY; Siegel JA; Kennel SJ; Goldenberg DM
Cancer Res; 1992 Nov; 52(21):6036-44. PubMed ID: 1394228
[TBL] [Abstract][Full Text] [Related]
40. Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model.
Hillairet De Boisferon M; Raguin O; Thiercelin C; Dussaillant M; Rostène W; Barbet J; Pélegrin A; Gruaz-Guyon A
Bioconjug Chem; 2002; 13(3):654-62. PubMed ID: 12009958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
